Embecta Corp. (EMBC)
Market Cap | 835.64M |
Revenue (ttm) | 1.13B |
Net Income (ttm) | 70.20M |
Shares Out | 57.67M |
EPS (ttm) | 1.21 |
PE Ratio | 11.94 |
Forward PE | 6.97 |
Dividend | $0.60 (4.15%) |
Ex-Dividend Date | May 28, 2024 |
Volume | 273,139 |
Open | 14.28 |
Previous Close | 14.20 |
Day's Range | 13.96 - 14.63 |
52-Week Range | 9.93 - 28.99 |
Beta | 0.82 |
Analysts | Sell |
Price Target | 13.00 (-10.03%) |
Earnings Date | May 9, 2024 |
About EMBC
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey. [Read more]
Financial Performance
In 2023, Embecta's revenue was $1.12 billion, a decrease of -0.77% compared to the previous year's $1.13 billion. Earnings were $70.40 million, a decrease of -68.52%.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for EMBC stock is "Sell" and the 12-month stock price forecast is $13.0.
News
Embecta (EMBC) CEO on Diabetes Treatment Market
Embecta (EMBC) CEO Dev Kurdikar joins Oliver Renick to give an overview of the company and discuss its 2Q earnings. He also talks about the impact of GLP-1 drugs.
Embecta Corp. Reports Second Quarter Fiscal 2024 Financial Results
PARSIPPANY, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three and six mon...
embecta Announces Quarterly Cash Dividend
PARSIPPANY, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding sh...
embecta to Participate in Investor Events
PARSIPPANY, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced that management ...
embecta to Report Fiscal Second Quarter 2024 Financial Results
PARSIPPANY, N.J., April 23, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to...
embecta-sponsored Educational Symposium and Abstracts at ATTD Highlight Role of Insulin Pumps in the Management of Type 2 Diabetes
PARSIPPANY, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced its sponsorshi...
Embecta Corp. Reports First Quarter Fiscal 2024 Financial Results
PARSIPPANY, N.J., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three month peri...
embecta to Participate in the 11th Annual BTIG MedTech Conference
PARSIPPANY, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will host one-on-one investor meetings on Tuesday, February 13, 2024, at the ...
embecta to Report Fiscal First Quarter 2024 Financial Results
PARSIPPANY, N.J., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to ...
embecta Announces FDA 510(k) Submission for Insulin Patch Pump
PARSIPPANY, N.J., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced that it has sub...
embecta to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
PARSIPPANY, N.J., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will present at the J.P. Morgan Healthcare Conference in San Francisco on Wed...
No embecta-made syringes impacted by FDA safety communication
PARSIPPANY, N.J., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company, today issued the following statement regarding the U.S. Food and Drug Admi...
embecta to Participate in Investor Conferences
PARSIPPANY, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company, today announced that management will participate in the following investor...
Embecta Corp. Reports Fiscal 2023 Fourth Quarter and Full Year Financial Results and Provides Initial Fiscal 2024 Financial Guidance
PARSIPPANY, N.J., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three- and twelv...
embecta to Recognize National Diabetes Awareness Month by Ringing Nasdaq Opening Bell
embecta (Nasdaq: EMBC), a global diabetes care company, announced it will ring the Nasdaq opening bell in recognition of National Diabetes Awareness Month.
embecta to Report Fiscal Fourth Quarter and Full Year 2023 Financial Results
PARSIPPANY, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company, will host a conference call to discuss its fiscal fourth quarter and full ...
embecta to Participate at the Morgan Stanley 21st Annual Healthcare Conference
PARSIPPANY, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will participate in a fireside chat at the Morgan Stanley 21st Annual Health...
Embecta Corp. Reports Third Quarter Fiscal 2023 Financial Results
PARSIPPANY, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three- and nine-...
embecta to Report Fiscal Third Quarter 2023 Financial Results
PARSIPPANY, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company, will host a conference call to discuss its fiscal third quarter 2023 finan...
UPDATE -- embecta to Participate in Investor Conferences
PARSIPPANY, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today announced that management will par...
Embecta Corp. Reports Second Quarter Fiscal 2023 Financial Results
PARSIPPANY, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today reported financia...
embecta and Tidepool partner to develop automated insulin delivery system for people with Type 2 diabetes
PARSIPPANY, N.J. and PALO ALTO, Calif., May 12, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, and Tidepool, a 50...
embecta to Report Fiscal Second Quarter 2023 Financial Results
PARSIPPANY, N.J., April 20, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, will host a conference call to discuss...
embecta sponsors educational symposium at ATTD 2023
Highlights the critical role people with diabetes play in their own care and treatment Highlights the critical role people with diabetes play in their own care and treatment
Embecta Corp. Reports First Quarter Fiscal 2023 Financial Results
PARSIPPANY, N.J., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today reported financi...